CD86 can be described as one of the two ligands (the other being CD80) to activate CTLA4 as well as CD28. CD86 is a costimulatory molecule for eliciting T-cell support in the course of antigen presentation. Antigen presentation without the presence of adequate co-stimulation with CD86/CD80 could trigger tolerance. CD80 seems to play a different role from CD80 in the differentiation of T helper cells.
CD86 is a membrane-bound type I protein, which is part of the superfamily immunoglobulin. The CD86 protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. You can know more about CD86 antibodies via www.bosterbio.com/anti-cd86-b7-2-picoband-trade-antibody-pb9251-boster.html.
The binding to CD86 to CD28 antigen acts as a costimulatory signal to activate the T-cell. The binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternate splicing results in two transcript variants, each encoding distinct variants of CD86.
Other transcript variants have been identified for CD86 however their full sequences have not been identified. Conditions that can be attributed to CD86 malfunction include gallbladder squamous-cell carcinoma and myocarditis. It is a GL1 monoclonal antibody that interacts with mouse CD86 that is an 80 kDa surface receptor, also called B7-2.
CD86 along with CD80 is part of the B7 family of costimulatory proteins. CD86 has been expressed to a lower level on macrophages, B cells as well as dendritic cells. CD86 is increased on B cells via a range of external stimuli, like CD40, the BCR complex CD40 as well as a few cytokine receptors. CD86 is also expressed by activated mouse T cells and thioglycolate-elicited peritoneal cells.